Adverse effects of antiretroviral therapy in HIV-1 infected children

Journal of Tropical Pediatrics

Volumn 52, Issue 4, 2006, Pages 244-248

  Shah, Ira ^a,b  

^a B J WADIA HOSPITAL FOR CHILDREN   (India)

^b NONE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLASE; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; ISONIAZID; LAMIVUDINE; LIVER ENZYME; NEVIRAPINE; RIFAMPICIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ABDOMINAL PAIN; ADOLESCENT; AMYLASE BLOOD LEVEL; ANEMIA; ANGIONEUROTIC EDEMA; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ERUPTION; DRUG WITHDRAWAL; FATTY LIVER; FEMALE; GENERAL HOSPITAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; LIVER TOXICITY; MALE; OUTPATIENT DEPARTMENT; PROSPECTIVE STUDY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; VIRUS LOAD;

ADOLESCENT; ANTI-HIV AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; MALE;

EID: 33748125363     PISSN: 01426338     EISSN: 14653664     Source Type: Journal    
DOI: 10.1093/tropej/fmi086     Document Type: Article

References (13)

1. Gold Schmidt RH, Dong BJ. Treatment of AIDS and HIV-related conditions - 2001. J Am Board Fam Pract 2001; 14: 283-309.
2. Boxwell DE, Styrt BA. Lactic acidosis in patients receiving nucleoside reverse transcriptase inhibitors. 39th Inter Science Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, 1999; Abstract No. 1284.
3. Kakuda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor - induced mitochondrial toxicity. Clin Ther 2000; 22(6): 685-708.
4. Butler KM, Venzon D, Henry N, et al. Pancreatitis in human immunodeficiency virus - infected children receiving dideoxyinosine. Pediatrics 1993; 91(4): 747-51.
5. Lewis LL, Venzon D, Church J, et al. Lamivudine in children with human immunodeficiency virus infection: A phase I/II study. The National Cancer Institute Pediatric Branch - Human Immunodeficiency Virus Working Group. J Infect Dis 1996; 174(1): 16-25.
6. Kline MW, Dunkle LM, Church JA, et al. A phase I/II evaluation of Stavudine (d4T) in children with human immunodeficiency virus infection. Pediatrics 1995; 96: 247-52.
7. McKinney RE, Maha MA, Connor EM, et al. A Multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. The Protocol 043 Study Group. N Engl J Med, 1991; 324(15): 1018-25.
8. Hervey PS, Perry CM. Abacavir: A review of its clinical potential in patients with HIV infection. Drugs 2000; 60(2): 447-79.
9. Shah I. Age Related Clinical Manifestations of HIV Infection in Indian Children. J Trop Pediatr 2005; 51(5): 300-3.
10. Working Group on Antiretroviral therapy and medical management of HIV-infected children. Antiretroviral therapy and medical management of Pediatric HIV infection. Pediatrics 1998; 102: 1005-62.
11. Nunez M, Lana R, Mendoza JL, et al. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 27(5): 426-31.
12. Fagot JP, Mockenhaupt M, Bouwes-Bavinck J-N, for the EuroSCAR Study Group. Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. AIDS 2001; 15(14): 843-48.
13. Lonergan JT, Behling C, Pfander H, et al. Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus - infected patients receiving nucleoside analogue combination regimens. Clin Infect Dis 2000; 31(1): 162-66.